Cell conversion technology developer Mogrify's founding team includes representation from the universities of Bristol and Monash, as well as Duke University - NUS Medical School.

Cell Mogrify, a UK-based cell conversion technology with links to research from multiple academic institutions, closed its seed round at $3.7m today with investors led by patient capital fund Ahren Innovation Capital.
The close followed an extension of undisclosed size and was backed by private equity firm 24Haymarket along with Cell Mogrify’s newly-appointed chief executive, Darrin Disley.
Details of the initial seed tranche have not been disclosed, though the announcement confirmed Cell Mogrify would now seek series…